Britain and America have forged a landmark trade agreement that will ensure no import taxes on British pharmaceutical exports being sold in the US market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has agreed to boost spending on pharmaceuticals through the public health system. This commitment ensures that import taxes on these key exports will remain at nothing for a timeframe of three years.
This agreement comes after previous threats to significantly raise import taxes on patented pharmaceutical imports, with increases floated up to double the cost.
"This arrangement with the UK strengthens the international landscape for cutting-edge drugs and brings much-needed equity to transatlantic pharmaceutical trade," a release declared.
Economic Significance
Drugs represent one of the UK's biggest export categories to the America, which is clearly the biggest market for leading British pharmaceutical firms.
Statistics reveal that in the 12 months to the end of September, the UK sold medicines worth billions to the US. This value made up a significant portion of British export trade in that span.
"This deal protects employment, stimulates capital expenditure and facilitates the UK to become a worldwide center for medical research," the Business and Trade Secretary remarked.
Key NHS Changes
The deal entails several notable changes from the British government:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it judges new treatments to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a goal to double overall public funding on drugs from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The percentage drug companies must refund to the NHS to control costs will be limited at fifteen percent. Last year, refunds topped 20%.
Recent Tensions
This agreement follows a long-running dispute between the sector and the ministers over drug pricing and regulatory access.
This friction were heightened by assertions that American consumers were paying significantly more for the equivalent treatments than consumers in the Britain and the EU.
In recent months, several large pharmaceutical investments in the UK have been delayed or abandoned, while multi-billion-dollar expansions have been directed toward American operations.
One official stated that the NHS had to increase expenditure on drugs, noting that its expenditure on drugs had declined as a share of its total funding over the previous ten-year period.
